Table 6.
Relative risk of significant CpG changes in immune pathways in pregnancy compared to random CpGs.
| Time | First Half of Pregnancy | Second Half of Pregnancy | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Association Based on Original p-Value | Association Based on FDR-Tested p-Value | Association Based on Original p-Value | Association Based on FDR-Tested p-Value | |||||||||
| Pathway (Total Number of CpGs) | Proportion of Significant CpGs | Risk Ratio | 95% Confidence Interval | Proportion of Significant CpGs | Risk Ratio | 95% Confidence Interval | Proportion of Significant CpGs | Risk Ratio | 95% Confidence Interval | Proportion of Significant CpGs | Risk Ratio | 95% Confidence Interval |
| Compared to 10 random subsets based on the whole genome | ||||||||||||
| Th1 (155) | 27.7 | 1.15 | 0.84–1.57 | 18.7 | 1.45 | 0.95–2.22 | 36.1 | 1.43 | 1.08–1.88 | 25.2 | 1.68 | 1.16–2.44 |
| Th2 (77) | 35.1 | 1.45 | 1.02–2.07 | 20.9 | 1.61 | 0.96–2.69 | 33.8 | 1.33 | 0.93–1.91 | 26.0 | 1.74 | 1.11–2.73 |
| Th17 (106) | 32.1 | 1.33 | 0.95–1.85 | 18.9 | 1.46 | 0.90–2.36 | 31.1 | 1.23 | 0.88–1.72 | 22.6 | 1.52 | 0.98–2.33 |
| Treg (10) | 30.0 | 1.24 | 0.47–3.26 | 20.0 | 1.55 | 0.44–5.51 | 40.0 | 1.58 | 0.72–3.44 | 30.0 | 2.01 | 0.75–5.35 |
| Random (Median proportion) | 24.1 | 12.9 | 24.6 | 14.9 | ||||||||
| Compared to 10 random subsets based on the genes expressed in CD4+ cells | ||||||||||||
| Th1 (155) | 27.7 | 1.16 | 0.84–1.59 | 18.7 | 1.30 | 0.86–1.97 | 36.1 | 1.35 | 1.03–1.78 | 25.2 | 1.72 | 1.18–2.49 |
| Th2 (77) | 35.1 | 1.46 | 1.02–2.09 | 20.9 | 1.45 | 0.87–2.40 | 33.8 | 1.26 | 0.88–1.81 | 26.0 | 1.77 | 1.13–2.79 |
| Th17 (106) | 32.1 | 1.34 | 0.96–1.87 | 18.9 | 1.31 | 0.82–2.10 | 31.1 | 1.17 | 0.84–1.62 | 22.6 | 1.55 | 1.00–2.38 |
| Treg (10) | 30.0 | 1.25 | 0.48–3.28 | 20.0 | 1.39 | 0.39–4.94 | 40.0 | 1.50 | 0.69–3.26 | 30.0 | 2.05 | 0.77–5.46 |
| Random (Median proportion) | 24.0 | 10.4 | 26.7 | 9.80 | ||||||||
The table shows the median risk ratios of significant changes of CpGs between age 18 years and pregnancy (22–24 years) in different immune pathways (Th1, Th2, Th17, Treg) compared to two sets of random samples of CpGs separate for the first and second halves of pregnancy.